Trial Profile
Pharmacodyanamics of brentuximab vedotin for the CD30 expression in patients with natural killer/T-cell lymphoma (NKTCL).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications T-cell lymphoma
- Focus Pharmacodynamics
- 12 May 2016 New trial record